Availability of extended-release buprenorphine to treat opioid use disorder for Medicaid-covered population

Ítems similars

• Extended-Release Naltrexone Versus Buprenorphine-Naloxone to Treat Opioid Use Disorder among Black Adults
  per: Haeny, Angela M., et al.
  Publicat: (2020)
• Predictors of availability of long-acting medication for opioid use disorder
  per: Shover, Chelsea L., et al.
  Publicat: (2019)
• Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
  per: Larance, Briony, et al.
  Publicat: (2020)
• A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
  per: Kranzler, Henry R, et al.
  Publicat: (2020)
• Priorities and concerns of people who use opioids are key to scaling up XR-buprenorphine
  per: Shover, Chelsea L.
  Publicat: (2020)